Trial Profile
Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sapropterin (Primary)
- Indications Hyperphenylalaninaemia
- Focus Therapeutic Use
- 10 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Aug 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2015 to 1 Dec 2015.
- 17 Aug 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Mar 2015 to 1 Dec 2015.